VEOZAH™ to be Featured in Four Oral Presentations at The Menopause Society Annual Meeting
Pooled Analyses Highlight Impact on Sleep Disturbance and Mood
– Pooled analyses from two SKYLIGHT™ studies showcase the impact of VEOZAH™ on sleep disturbance and impairment in women experiencing moderate to severe vasomotor symptoms (VMS) due to menopause. The studies demonstrated a significant improvement in sleep quality and reduction in sleep disturbances in women receiving treatment with VEOZAH™. In addition, the relationship between improvements in the frequency or severity of hot flashes and mood was examined, showing a positive correlation between VEOZAH™ treatment and mood enhancement.
Safety and Tolerability in Hispanic/Latina Women
– Pooled data from three SKYLIGHT™ studies evaluated the safety and tolerability of VEOZAH™ in Hispanic/Latina women. The results indicate that VEOZAH™ is well-tolerated with a favorable safety profile in this population, providing a new treatment option for women of diverse backgrounds experiencing VMS.
Responder Analysis in Women Unwilling or Unable to Take Hormone Therapy
– Responder analysis from the DAYLIGHT™ study examined the reduction in VMS frequency in women who are unwilling or unable to take hormone therapy for menopausal symptoms. The results showed that VEOZAH™ effectively reduced VMS frequency in this population, offering a non-hormonal treatment option for women who cannot or do not wish to use hormone therapy.
TOKYO , Sept. 4, 2024 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announced that VEOZAH™ (fezolinetant), its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be featured in four oral presentations during the 2024 Annual Meeting of The Menopause Society (TMS) September 10-14 in Chicago.
How Will This Affect Me?
As a woman experiencing menopausal symptoms, the introduction of VEOZAH™ could offer a new and effective treatment option for managing vasomotor symptoms such as hot flashes and sleep disturbances. The findings presented at the TMS Annual Meeting demonstrate the potential benefits of VEOZAH™ in improving quality of life during this transitional phase.
How Will This Affect the World?
The availability of VEOZAH™ as a non-hormonal treatment for menopausal symptoms could have a significant impact on women’s health worldwide. By providing a safe and effective alternative to traditional hormone therapy, VEOZAH™ has the potential to improve the quality of life for women experiencing vasomotor symptoms, regardless of their background or treatment preferences.
